TABLE 22Measures of global effect in included studies: rivastigmine vs placebo

StudySubgroupOutcomeTypeArmRivastigminePlacebop-value
NMean, n (%)NMean, n (%)
Feldman and Lane (2007)138ITT populationCIBIC-plus score – 18 weeksAb.i.d.2154.1 (SD 1.03)a2134.5 (SD 1.02)a≤ 0.001b
t.i.d.2203.9 (SD 1.04)a≤ 0.001b
CIBIC-plus score – 26 weeksAb.i.d.2224.1 (SD 1.3)2164.5 (SD 1.3)≤ 0.001c
t.i.d.2223.9 (SD 1.3)< 0.05c
CIBIC-plus: any improvement – 12 weeksDb.i.d.22066 (30.0)a21334 (16.0)a≤ 0.001d
t.i.d.21562 (28.8)a< 0.05d
CIBIC-plus: any improvement – 18 weeksDb.i.d.22068 (30.9)a21340 (18.8)a≤ 0.001d
t.i.d.21547 (21.9)aNSd
CIBIC-plus: any improvement – 26 weeksDb.i.d.22068 (30.9)a21340 (18.8)a< 0.05d
t.i.d.21549 (22.8)aNSd
GDS – 26 weeksMCb.i.d.2270 (SD 0.7)222−0.3 (SD 0.7)< 0.05b
t.i.d.229−0.2 (SD 0.7)NSb
LOCF analysisCIBIC-plus score – 26 weeksAb.i.d.2063.9 (SD 1.2)2054.5 (SD 1.2)≤ 0.001c
t.i.d.1984.1 (SD 1.2)< 0.05c
GDS – 26 weeksMCb.i.d.1950 (SD 0.7)202−0.3 (SD 0.7)< 0.05b
t.i.d.188−0.1 (SD 0.7)NSb
OC populationCIBIC-plus score – 26 weeksAb.i.d.1773.9 (SD 1.2)1794.4 (SD 1.2)≤ 0.001c
t.i.d.1674.1 (SD 1.2)< 0.05c
Winblad et al. (2007)140LOCF analysisADCS-CGIC: score – 16 weeksA10e2483.9 (SD 1.14)f2784.35 (SD 1.25)fNSg
20h2603.93 (SD 1.17)fNSg
Oral2534.25 (SD 1.11)fNSg
ADCS-CGIC: score – 24 weeksA10e2483.9 (SD 1.2)2784.2 (SD 1.3)0.01g
20h2604 (SD 1.3)0.054g
Oral2533.9 (SD 1.3)0.009g
ADCS-CGIC: markedly improved – 24 weeksD10e2485 (2.0)2782 (0.7)0.361i
20h2605 (1.9)0.395i
Oral2533 (1.2)0.916i
ADCS-CGIC: moderately improved – 24 weeksD10e24829 (11.7)27826 (9.4)0.463i
20h26032 (12.3)0.334i
Oral25329 (11.5)0.513i
ADCS-CGIC: minimally improved – 24 weeksD10e24843 (17.3)27850 (18.0)0.937i
20h26048 (18.5)0.975i
Oral25360 (23.7)0.129i
ADCS-CGIC: unchanged – 24 weeksD10e248105 (42.3)27891 (32.7)0.029i
20h26094 (36.2)0.457i
Oral25396 (37.9)0.244i
ADCS-CGIC: minimally worse – 24 weeksD10e24841 (16.5)27865 (23.4)0.065i
20h26050 (19.2)0.285i
Oral25330 (11.9)< 0.001i
ADCS-CGIC: moderately worse – 24 weeksD10e24822 (8.9)27836 (12.9)0.177i
20h26027 (10.4)0.429i
Oral25330 (11.9)0.803i
ADCS-CGIC: markedly worse – 24 weeksD10e2483 (1.2)2788 (2.9)0.303i
20h2604 (1.5)0.448i
Oral2535 (2.0)0.696i

A, absolute value; b.i.d., twice a day; D, dichotomous; MC, mean change; t.i.d, three times a day.

a

Estimated from figure.

b

The t-test using pooled error term from analysis of covariance (ANCOVA)/analysis of variance ANOVA (SAS type III analysis).

c

The t-test using pooled error term from ANOVA (SAS type III).

d

Mantel–Haenszel test.

e

A 10-cm2 rivastigmine patch – equivalent to 9.5 mg/day.

f

Data extracted from figure.

g

Cochran–Mantel–Haenszel van Elteren test using modified ridit scores stratified by country.

h

A 20-cm2 rivastigmine patch – equivalent to 17.4 mg/day.

i

Chi-squared test (Yates' correction) (calculated by reviewer).

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.